Imugene Limited (ASX: IMU)
Australia
· Delayed Price · Currency is AUD | Market Cap | 282.62M |
| Revenue (ttm) | 4.97M |
| Net Income (ttm) | -149.68M |
| Shares Out | 7.44B |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,295,359 |
| Open | 0.0360 |
| Previous Close | 0.0360 |
| Day's Range | 0.0360 - 0.0380 |
| 52-Week Range | 0.0350 - 0.1300 |
| Beta | 3.34 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 27, 2024 |
About Imugene
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tum... [Read more]
Financial Performance
In 2024, Imugene's revenue was 4.97 million, a decrease of -57.80% compared to the previous year's 11.78 million. Losses were -149.68 million, 294.8% more than in 2023.
Financial StatementsNews
Imugene Ltd Azer-cel Trial Update Transcript
Imugene Ltd Azer-cel Trial Update Transcript
Bile Tract Cancer expansion study opens following clearance of Imugene's MAST trial high dose cohort
The expansion trial is expected to enrol 10 patients with bile tract cancers (cholangiocarcinoma) Interim results from the MAST trial have demonstrated positive responses in gastrointestinal cancers, ...
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024
Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients. Encouraging VAXINIA efficacy, including a complete response (CR) and ...
Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts
Five clinical trials across three prioritized immuno-oncology platforms with encouraging safety and efficacy signals Encouraging early results from the VAXINIA (CF33) oncolytic virus trial, including ...
Imugene's CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers Symposium
SYDNEY, AUSTRALIA / ACCESSWIRE / January 18, 2024 / Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce further details from its poster presentation at the ASCO...
NeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatments
The collaboration will evaluate the ability of NeoImmuneTech's immune cell amplifier NT-I7 to increase the number of azer-cel allogeneic CAR T cells per batch during manufacturing. The combination pot...
City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors
SYDNEY & LOS ANGELES--(BUSINESS WIRE)--Imugene Limited and City of Hope's first patient was dosed in a clinical trial evaluating the safety of new cancer-killing virus CF33-hNIS VAXINIA.
Imugene Announces Clinical Trial Collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to Evaluate HER-Vaxx in Combination with Pembrolizumab for Treatment of Gastric Cancer
SYDNEY, Australia, March 14, 2022 (GLOBE NEWSWIRE) -- Imugene (ASX: IMU) today announced a new clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth,...
Imugene and Eureka Therapeutics Announce Strategic Collaboration to Accelerate Advancement of Oncolytic Virus and T-Cell Therapy in Solid Tumours
SYDNEY & EMERYVILLE, Calif.--(BUSINESS WIRE)--Imugene Ltd (“Imugene”) (ASX: IMU), a clinical stage immuno-oncology company, and Eureka Therapeutics, Inc. (“Eureka”), a clinical-stage biotechnology com...